Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL noninferiority randomized trial

MLA

Laure Huot, et al. Ranibizumab versus Bevacizumab for Neovascular Age-Related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Jan. 2013. EBSCOhost, https://doi.org/10.1111/j.1755-3768.2013.4461.x〉.

APA

Laure Huot, Laurent Kodjikian, Evelyne Decullier, G. Mimoun, Martine Mauget-Faÿsse, Francine Behar-Cohen, Eric H. Souied, & Gilles Aulagner. (2013). Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL noninferiority randomized trial. https://doi.org/10.1111/j.1755-3768.2013.4461.x〉

Chicago

Laure Huot, Laurent Kodjikian, Evelyne Decullier, G. Mimoun, Martine Mauget-Faÿsse, Francine Behar-Cohen, Eric H. Souied, and Gilles Aulagner. 2013. “Ranibizumab versus Bevacizumab for Neovascular Age-Related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial,” January. doi:10.1111/j.1755-3768.2013.4461.x〉.